Valuation: Laboratorios Farmaceuticos Rovi, S.A.

Market Cap 3.06B 3.57B 2.86B 2.62B 4.92B 342B 4.98B 33.81B 13.18B 172B 13.41B 13.11B 568B P/E 2026 *
21.4x
P/E 2027 * 17.7x
Enterprise Value 3.04B 3.55B 2.85B 2.61B 4.89B 340B 4.95B 33.63B 13.11B 171B 13.34B 13.05B 565B EV / Sales 2026 *
3.94x
EV / Sales 2027 * 3.34x
Free-Float
31.63%
Yield 2026 *
1.61%
Yield 2027 * 1.95%
1 day-0.17%
1 week+3.19%
Current month+2.13%
1 month+9.32%
6 months-23.87%
Current year-5.83%
1 week 57.3
Extreme 57.3
61
1 month 56.6
Extreme 56.6
61
Current year 53.1
Extreme 53.1
86.7
1 year 53.1
Extreme 53.1
86.7
3 years 45.52
Extreme 45.52
94.8
5 years 35.2
Extreme 35.2
94.8
10 years 10.8
Extreme 10.8
94.8
Manager TitleAgeSince
Chief Executive Officer - 27/07/2007
Director of Finance/CFO - 01/01/2001
Chief Operating Officer - -
Director TitleAgeSince
Chairman - 17/07/2021
Director/Board Member - 27/07/2007
Director/Board Member - 27/07/2007
Date Insider Type Main position Quantity % Market Cap.
23/06/23 Buy

Director

1,000 0.0019%
13/04/22
Norbel Inversiones SL
SellCompany 560,690 1.0000%
15/03/22
Norbel Inversiones SL
SellCompany 2,803,448 5.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-0.17%+3.19%+4.82%+23.50% 3.58B
+0.88%+6.38%+76.86%+128.23% 1,109B
+1.07%+3.80%+51.03%+61.48% 644B
+1.20%+6.21%+26.47%+76.45% 463B
+1.02%+5.77%+43.09%+47.70% 371B
+0.85%+4.07%+23.88%+41.58% 301B
+1.26%+6.81%+1.59%+14.67% 256B
+1.88%+5.81%+48.54%+68.52% 234B
+1.59%+2.09%-15.52%-52.29% 205B
+1.87%+5.61%+25.81%+92.42% 178B
Average +1.14%+4.00%+28.66%+50.23% 376.46B
Weighted average by Cap. +1.14%+4.47%+44.30%+72.54%

Financials

2026 *2027 *
Net sales 772M 901M 722M 661M 1.24B 86.19B 1.26B 8.53B 3.33B 43.3B 3.38B 3.31B 143B 891M 1.04B 833M 763M 1.43B 99.5B 1.45B 9.85B 3.84B 49.98B 3.9B 3.82B 165B
Net income 129M 150M 120M 110M 207M 14.36B 209M 1.42B 554M 7.21B 563M 551M 23.86B 174M 203M 163M 149M 280M 19.42B 283M 1.92B 750M 9.76B 762M 746M 32.27B
Net Debt -16.21M -18.93M -15.17M -13.89M -26.06M -1.81B -26.41M -179M -69.9M -910M -71.07M -69.53M -3.01B -81.51M -95.15M -76.26M -69.81M -131M -9.1B -133M -901M -351M -4.57B -357M -350M -15.13B
Logo Laboratorios Farmaceuticos Rovi, S.A.
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows: - prescription pharmaceuticals (49%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.; - pharmaceutical products manufactured under contract (44%); - diagnostic products (7%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals. Net sales break down by source of revenue between sales of products (95.4%) and sales of services (4.6%). Net sales are distributed geographically as follows: Spain (77%), Italy (5%), Germany (3%), Portugal (2%), France (1%), Greece (1%) and other (11%).
Employees
2,470
Date Price Change Volume
21/08/26 €59.80 -0.17% 74,919
20/08/26 €59.90 +0.34% 171,340
19/08/26 €59.70 +2.93% 325,296
18/08/26 €58.00 +0.69% 53,351
17/08/26 €57.60 -0.60% 111,523
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
59.80EUR
Average target price
74.36EUR
Spread / Average Target
+24.34%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ROVI Stock